anamorelin
Small moleculeexperimental
Anamorelin is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is under development by Helsinn Healthcare SA for the treatment of cancer cachexia and anorexia. — Wikipedia
Clinical trial activity
14 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
12
Phase 3
6
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00219817)
Timeline
Indications
Mechanism of action
- Ghrelin receptorAGONIST
GHSR agonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1- Mol. weight
- 546.72 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2110579 ↗
- WikipediaAnamorelin ↗
- ChEMBLCHEMBL2103794 ↗
Also known as
- anamorelin
- anamorelin
- anamorelin
- anamorelin
- anamorelin hcl
- anamorelin hcl
- anamorelin hydrochloride
- anamorelin hydrochloride
- anamorelin hydrochloride
- anamorelin hydrochloride
- anamorelin hydrochloride
- ono-7643
- ono-7643
- ono-7643
- rc-1291
- rc-1291
- rc-1291
- rc-1291 hcl
- rc-1291 hcl
- rc-1291 hcl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04844970 | Phase 2 | Sep 30, 2021 | Helsinn, Quartesian LLC, Tufts University |
| NCT04021706 | Phase 1 | Aug 31, 2019 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Tufts University |
| NCT03637816 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2018 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03743064 | Phase 3 | Dec 18, 2018 | Helsinn |
| NCT03743051 | Phase 3 | Dec 18, 2018 | Helsinn |
| NCT03035409 | Phase 2 | Feb 8, 2017 | Helsinn, University of Texas at Houston |
| NCT01505764 | Phase 2 | Jun 1, 2012 | Department of Veteran Affairs, Helsinn |
| NCT01387269 | Phase 3 | Jul 1, 2011 | Helsinn |
| NCT01395914 | Phase 3 | Jul 1, 2011 | Helsinn |
| NCT01387282 | Phase 3 | Jul 1, 2011 | Helsinn |
| NCT00622193 | Phase 2 | Mar 1, 2008 | Harvard University, Helsinn |
| NCT00378131 | Phase 2 | Sep 1, 2006 | Helsinn |
| NCT00267358 | Phase 2 | Nov 1, 2005 | Helsinn |
| NCT00219817 | Phase 2 | Jun 1, 2005 | Helsinn, Sapphire Therapeutics |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Helsinn | For profit | 12 | 9 | 2 | 2005 |
| Tufts University | Academic/Hospital | 2 | 2 | 2 | 2019 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2017 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2012 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 0 | 1 | 2019 |
| Quartesian LLC | For profit | 1 | 0 | 1 | 2021 |
| Sapphire Therapeutics | For profit | 1 | 0 | 1 | 2005 |
9 organizations
Page 1 / 1